GlassScriptPhysician profile
Inna Janas
NPI 1972698736
$2,131.38
in general payments reported to CMS, 2019-2025
10 companies · $273 in 2025
The $273 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $250 · 2022: $534 · 2023: $245 · 2024: $830 · 2025: $273.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,347.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,347.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $502.77 | 2022-2025 | Nuplazid |
| Astrazeneca Pharmaceuticals LP | $382.49 | 2022-2023 | Lokelma |
| Argenx US, INC. | $350.60 | 2024-2025 | Vyvgart, Vyvgart Hytrulo |
| Amryt Pharma Holdings LTD | $150.01 | 2022 | |
| Alexion Pharmaceuticals, INC. | $134.99 | 2024 | Ultomiris |
| Lilly USA, LLC | $125.00 | 2023 | Mounjaro |
| Biohaven Pharmaceuticals, INC. | $125.00 | 2021 | |
| Abbvie INC. | $124.99 | 2021 | |
| Phathom Pharmaceuticals, INC. | $120.53 | 2024 | Voquezna |
| Corcept Therapeutics | $115.00 | 2024 | Korlym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Inna Janas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.